Abstract
In the last few years calcium antagonists have been reported to act as antiatherosclerotic agents independently from any modification of risk factors. Since these compounds have no adverse effect on plasma lipoproteins profile and are effective antihypertensives, they may represent first-line drugs in this field. However, contrasting results are reported in the literature on the antiatherogenic effect of calcium antagonists in experimental animals, and only preliminary data exist on the effect in humans. This paper summarizes the main in vivo and in vitro studies so far conducted in this field and focuses on the mechanisms by which calcium antagonists may exert their antiatherosclerotic action.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Opie LH. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review. Quart J Med 1984; New Series LIII/209:1–16.
Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981; 68: 1366–1369.
Willis AL, Nagel B, Churchill V et al. Antiatherosclerotic effect of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis 1985; 5: 250–255.
Overturf ML, Smith SA. Failure of a high therapeutic dosage of nifedipine to suppress atherogenesis in cholesterol-fed rabbits. Arteriosclerosis 1982; 2: A408.
Stender S, Stender I, Nordestgaard B, Kjedsen K. No effect of nifedipine on atherogenesis in cholesterol-fed rabbits. Arteriosclerosis 1984; 4: 389–394.
Ohata I, Sakamoto N, Nagano K, Maeno H. Low density lipoprotein-lowering and high density lipoprotein-elevating effects of nicardipine in rats. Pharmacol 1984; 33: 2199–2205.
Kritchevsky D, Tepper SA, Klurfeld DM. Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1988; 69: 89–92.
Overturf ML, Sybers H, Schaper J, Taegtmayer H. Hypertension and atherosclerosis in cholesterol-fed rabbits.II. One kidney-one clip Goldblatt hypertension treated with nifedipine. Atherosclerosis 1987; 66: 68–73.
Thiery J, Niedmann PD, Seidel D. The beneficial influence of nifedipine on the regression of the cholesterol-induced atherosclerosis in rabbits. Exptl Med 1987; 187: 359–376.
Pauletto P, Sartore S, Scannapieco G et al. Immunocytochemical analysis of myosin isoform distribution in the atherosclerotic lesions of cholesterol-fed rabbits. In: Hypertension and Atherosclerosis, C Dal Palu’, R Ross, eds., Excerpta Medica, 1989: 107–112.
Pauletto P, Sartore S, Borrione A C et al. A nifedipine-sensitive smooth muscle cell subpopulation in the aortic media of hypercholesterolemic rabbit.X International Symposium on drugs affecting lipid metabolism.November 8–11, 1989 Houston, Texas, (abstract )
Lichtlen PB, Hugenholtz PG, Rafflenbeul W, Jost S, and the INTACT Study Group. Retardation of the progression of coronary artery disease in man by nifedipine; the international nifedipine trial on antiatherosclerotic therapy, in: Focus on Adalat.
Handley DA, Van Valen RG, Melden MK, Saunders RN. Suppression of rat carotid lesion development by the calcium channel blocker PN-200-110. Am J Pathol 1986; 124: 88–93.
Habib JB, Bossaller C, Wells S. Preservation of endothelium-dependent vascular relaxation in Cholesterol-fed rabbits by treatment with calcium blocker PN-200-110. Circ Res 1986; 58: 305 309.
Rouleau JL, Parmley WW, Stevens J et al. Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. J Am Coll Cardiol 1983; 1 (6): 1453–1460.
Blumstein SL, Sievers R, Kidd P, Parmley WW. Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am J Cardiol 1984; 54: 884–889.
Sugano M, Nakashima Y, Matsuchima T et al. Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injections. Arteriosclerosis 1986; 6: 237–241.
Ginsberg R, Davis K, Bristow MR et al. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest 1983; 9: 154–158.
Naito M, Kuzuya F, Asai K et al. Ineffectiveness of Ca++ antagonists nicardipine and diltiazem on experimental atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1984; 51: 343–344.
Nilsson J, Sjolund M, Palmerg L et al. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis, 1985; 58: 109–122.
Nomoto A, Hirosumi J, Sekiguchi C et al. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Atherosclerosis, 1987; 64: 255–261.
Schmitz G, Robenek H, Beuck M et al. Ca++ antagonist and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis, 1988; 8: 46–56
Robenek H and Schmitz G. Ca++ antagonist and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms.II. Arteriosclerosis, 1988; 8: 57–67
Stein O, Leitersdorf E, Stein Y. Verapamil enhances receptor-mediated endocytosis of low-density lipoproteins by aortic cells. Arteriosclerosis, 1985; 5: 35–44.
Stein O, Halperin G, Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis, 1987; 7: 585–592.
Orekhov A, Tertov V, Khashimov K et al. Evidence of antiatherosclerotic action of verapimil from direct effects on arterial cells. Am J Cardiol 1987; 59: 495–496.
Pauletto P, Angelini A, Vescovo G et al. The surface measurement of aortic atherosclerosis: critical survey and comparison with histologic findings. Int J Cardiol 1985; 8: 361–373.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers
About this chapter
Cite this chapter
Pauletto, P., Scannapieco, G. (1990). Do calcium antagonists inhibit atherogenesis?. In: Descovich, G., Gaddi, A., Magri, G., Lenzi, S. (eds) Atherosclerosis and Cardiovascular Disease. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0731-7_45
Download citation
DOI: https://doi.org/10.1007/978-94-009-0731-7_45
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6814-7
Online ISBN: 978-94-009-0731-7
eBook Packages: Springer Book Archive